New insider activity at Glaukos ( (GKOS) ) has taken place on March 1, 2025.
President & CEO Mark J. Foley has sold 20,687 shares of Glaukos stock, amounting to a total sale value of $2,497,334.
Recent Updates on GKOS stock
Glaukos Corp. has recently experienced significant developments, notably receiving a ‘Day 74′ notification from the FDA for its New Drug Application for Epioxa, a next-generation corneal cross-linking therapy. This marks a critical step towards providing the first FDA-approved, non-invasive treatment for keratoconus. The company’s strong financial performance in Q4 2024, with record net sales driven by its glaucoma segment, has bolstered investor confidence. Analysts have raised Glaukos’ price targets, citing robust iDose revenue growth and promising clinical advancements, including positive Phase III trial results for iDose TR. Despite challenges such as LCD impacts and foreign exchange headwinds, Glaukos’ solid financial position and strategic direction, including a strong cash reserve and no debt, support its ambitious sales guidance for 2025.
More about Glaukos
YTD Price Performance: -20.94%
Average Trading Volume: 687,865
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $6.69B